top of page
31, 2023 January
Cornell University And Thai Leaf Collaborate To Design New Hemp And CBD Strains In Thailand
CThai Leaf Biotechnology, a private company in the hemp industry, and Cornell University will collaborate in the design and development of new hemp strains that are high in CBD and adapted to Thailand’s weather.. More...
August 19, 2022
Thai Leaf taps US experts as Thailand eyes billion-dollar hemp market
Aiming to be a one-stop service for high-quality hemp products, Thai Leaf has joined hands with local property developer Origin, CannaPharma of Canada, Singapore’s Eralian Capital and Cornell University in the United States.
July 26, 2021
Legislative overhaul may help pot companies to go public in the US, either by giving banks leeway or changing the drug's legal status. That could set up a crucial exit option for privately backed cannabis companies, ending the need for workarounds like listing shares in Canada or banking with state-chartered credit unions.
April 29, 2021
Coverage on Cybin, With Buy Rating And USD$10 Price Target
March 08, 2021
With the commencement of trading on the OTCQB, Cybin has achieved another important milestone on its path to advancing mental health care through evidenced-based therapeutics.
July 26, 2021
Cannapharma enters in Thai cannabis market
Cannapharma signed a term sheet with Thai Leaf Biotechnology Co. Ltd to invest in Thai market. More...
July 28, 2021
Cybin Receives Final Approval to Commence Trading on the NYSE American on or About August 5
May 04, 2021
Cybin Inc.’s primary focus is to take classical psychedelic molecules and transform them into useful therapeutic agents for mental health disorders. “We have a global issue and inadequate treatments. And that’s the problem we’re trying to solve,” says, CEO Doug Drysdale
Oct. 09, 2020
Psilocybin assisted psychotherapy is currently being widely studied as a treatment for a range of mental health conditions including depression, anxiety, and substance use disorders. Simultaneously, Cybin is structuring and supporting clinical studies across North America and other regions, through strategic academic and institutional partnerships.
April 11, 2021
CYBN has potential to become a solid psychedelic biopharma player; initiating with a BUY, C$8PT
Oct. 19, 2020
Cybin and Clarmin Announce Closing of CDN$45 Million Oversubscribed Private Placement and Provide Update on RTO
Nov. 11 2020
Cybin Inc., a Canadian pharmaceutical development startup focused on psychedelic drugs, went public on the NEO Exchange in Toronto on Monday through a reverse takeover. Cybin’s stock jumped 23% during the first two days of trading.
Dec. 27, 2020
All in all, no other country offers the same package to fuel CannaPharma’s aspirations. In one year, CannaPharma has reached a valuation of $37 million (all figures U.S.) and attracted venture capital funds and individual investors from the Netherlands and Turkey, Altug said.
Dec. 29, 2020
CannaPharma Inc., for example, whose founders’ native Turkey strictly limits marijuana use, is growing through acquisitions and ventures in the U.S., Jamaica, Portugal and Abu Dhabi. “We want to grow in everything cannabis,” Altug said in an interview.
Sep. 24 2020
First psychedelic company to IPO on NASDQ: Compass Pathways IPO Brings $1 Billion Valuation
Dec. 10 2019
Global Canna Labs exports from Jamaica to Canada
Jul. 11 2020
Companies like Growpacker have seen the potential of combining automated solutions with manual processing, and such companies will become key players in the growth of the cannabis industry.
Nov. 11 2020
Reflections of US Elections in the market
Feb. 11 2020
Vertically integrated business models are already lapping up customers. Models like Growpacker enable brands to go from concept to dispensary shelf with minimal overhead costs.
bottom of page